Our division is home to one of the only programs dedicated to treating people with uncommon gynecologic malignancies — the Center for Rare Gynecologic Cancers. Our center emphasizes personalized care for people with uterine sarcomas, low-grade serous ovarian carcinoma, uterine serous carcinoma, clear cell and mucinous tumors of the ovary, germ cell and sex cord stromal tumors of the ovary, vulvar melanoma, neuroendocrine carcinoma of the cervix and gestational trophoblastic tumors.
The complexity of these cancers requires a team specialized in providing advanced treatment. Amanda Fader, M.D., is a national leader in rare gynecologic cancer research and has focused much of her work on treating people with these rare cancers and offering them innovative, individualized and targeted therapies.
As a member of the rare tumor group of the National Cancer Institute's NRG Oncology, Dr. Fader and her colleagues offer the most state-of-the-art clinical trials for people with uncommon malignancies.
Where you decide to go for care has a major effect on your outcome. Our experts are determined to combat the rarest gynecologic cancers.